Oncovita
PrivateLast Round
VC Round
Jun 25, 2026
Total Funding Raised
$8.78M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Oncovita is a biotechnology company that develops virus-derived vaccine technology to treat various types of cancers and infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Oncovita Comparables
Compare Oncovita with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CanVirex AG | 85% | |
| Vyriad | 83% | |
| Imugene Ltd | 78% | |
Oncovita Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jun 25, 2026 | ||||
| Angel | Nov 29, 2023 | ||||
| Grant | Nov 29, 2023 |
Oncovita Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bpifrance | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 25, 2026
$23M raised in a VC Round.
- May 14, 2026
Monthly visitors increased 60% MoM.
Oncovita Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Oncovita's valuation, stock price, and market status.